Immune Biomarkers Related to Bone Pathology in Patients With Type 1 Gaucher Disease

Study Overview
=================
Brief Summary
-----------------
Bone-related problems represent the principal unmet medical need in Gaucher disease (GD). 75% of GD type 1 patients develop skeletal complications, including bone remodeling defects, osteopenia, osteoporosis, marrow infiltration, avascular necrosis, and osteolysis. However, the underlying cellular/molecular basis of bone involvement and related complications in GD are not fully known. Neither are there any bone-specific markers associated with individual bone pathology. Early diagnosis of bone disease is the key issue for planning individual therapy to prevent and reverse bone disease in GD.

Detailed Description
-----------------
This clinical observational study is designed to identify specific biomarkers for bone involvement in patients with GD1 with decreased bone density and/or bone structural abnormalities Aims: Identify novel immune cell surface and biochemical markers in peripheral blood correlating with bone involvement in GD. Assess the correlation between cytokine levels in peripheral blood and the severity of bone involvement in GD. Assess the relationship between glycosphingolipids accumulation and macrophage activation with specific bone markers and GD severity.

Official Title
-----------------
Immune Biomarkers Related to Bone Pathology in Patients With Type 1 Gaucher Disease

Conditions
-----------------
Gaucher Disease Type 1

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: To be enrolled in this study the subject must meet the following criteria Subject is greater than 16 years old but not older than 90 years Signed Informed Consent/Assent Subject is able and willing to sign informed consent or assent If the subject has GD1, the must have a confirmed diagnosis of Gaucher disease by GCase enzyme activity DNA analysis demonstrating pathogenic variants in the GBA gene Exclusion Criteria: a) Have evidence of hepatitis B, hepatitis C infection or any other chronic infectious disease b) Be pregnant or breastfeeding

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| GD1 subjects with no bone complications<br>1. GD1 subjects with no bone complications (n=10) | |
| GD1 patients with mild bone complication<br>2. GD1 subjects with mild bone complications | |
| GD1 with severe bone complications<br>3. GD1 subjects with severe bone complications | |
| No bone disease<br>Controls with no known bone disease (n=10) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measure biomarkers level in molar/l/h | Bone homeostasis is dependent on the balance of deposition by osteoblasts DMP-1, OSCAR, Calcitonin, Lyso-GB1, chitotriosidase, CCL18, osteocalcin, BALP, cathepsin K , TRAP 5, RANKL, OPG, DDK-1, sclerostin, MCP1, IL-2, IL-6, IL-10, SRTH2 and TNF-α | 18 months | 
| Measure biomarkers level: molar/mg/h | DMP-1, RANK, OSCAR, cathepsin K, OPG | 18 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Gaucher disease, Osteoporosis